| 000 | 01910 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515062130.0 | ||
| 264 | 0 | _c20070628 | |
| 008 | 200706s 0 0 eng d | ||
| 022 | _a0142-2782 | ||
| 024 | 7 |
_a10.1002/bdd.544 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiura, Masatomo | |
| 245 | 0 | 0 |
_aInfluence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. _h[electronic resource] |
| 260 |
_bBiopharmaceutics & drug disposition _cMay 2007 |
||
| 300 |
_a167-75 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a2-Pyridinylmethylsulfinylbenzimidazoles _xpharmacology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xdrug effects |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C19 |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xdrug effects |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGenes, MDR _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xblood |
| 650 | 0 | 4 | _aKidney Transplantation |
| 650 | 0 | 4 | _aLansoprazole |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xdrug effects |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aRabeprazole |
| 650 | 0 | 4 |
_aTacrolimus _xblood |
| 700 | 1 | _aInoue, Kazuyuki | |
| 700 | 1 | _aKagaya, Hideaki | |
| 700 | 1 | _aSatoh, Shigeru | |
| 700 | 1 | _aTada, Hitoshi | |
| 700 | 1 | _aSagae, Yoshinori | |
| 700 | 1 | _aHabuchi, Tomonori | |
| 700 | 1 | _aSuzuki, Toshio | |
| 773 | 0 |
_tBiopharmaceutics & drug disposition _gvol. 28 _gno. 4 _gp. 167-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/bdd.544 _zAvailable from publisher's website |
| 999 |
_c16932684 _d16932684 |
||